The place of observational studies in assessing the effectiveness of depot antipsychotics

Schizophrenia Research

Volumn 131, Issue 1-3, 2011, Pages 260-261

  Haddad, Peter M ^a,b   Tiihonen, Jari ^c   Haukka, Jari ^d   Taylor, Mark ^e   Patel, Maxine X ^f   Korhonen, Pasi ^d  

^a GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d EPID Research Oy   (Finland)

^e NHS LOTHIAN   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; PERPHENAZINE DECANOATE; RISPERIDONE; ZUCLOPENTHIXOL DECANOATE;

CLINICAL PRACTICE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HOSPITAL READMISSION; HUMAN; LETTER; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 80051781169     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.05.022     Document Type: Letter

References (11)

1. Adams C.E., Fenton M.K., Quraishi S., David A.S. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry 2001, 179:290-299.
2. Haddad P.M., Taylor M., Niaz O.S. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br. J. Psychiatry Suppl. 2009, 52:S20-S28.
3. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J., Association American Psychiatric Practice guideline for the treatment of patients with schizophrenia. Am. J. Psychiatry 2004, 161(2 Suppl):1-56. Steering Committee on Practice Guidelines, second edition.
4. Leucht C., Heres S., Kane J.M., Kissling W., Davis J.M., Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 2011, 127(1-3):83-92.
5. NICE Schizophrenia (CG82). Core interventions in the treatment and management of schizophrenia in primary and secondary care (update) 2009, Issue date: March 2009.
6. Patel M.X., Haddad P.M., Chaudhry I.B., McLoughlin S., Husain N., David A.S. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5years. J. Psychopharmacol. 2010, 24(10):1473-1482.
7. Rosenheck R.A., Krystal J.H., Lew R., Barnett P.G., Fiore L., Valley D., Thwin S.S., Vertrees J.E., Liang M.H., CSP555 Research Group Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N. Engl. J. Med. 2011, 364(9):842-851.
8. Shi L., Ascher-Svanum H., Zhu B., Faries D., Montgomery W., Marder S.R. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr. Serv. 2007, 58(4):482-488.
9. Taylor M., Currie A., Lloyd K., Price M., Peperell K. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J. Psychopharmacol. 2008, 22(2):128-131.
10. Tiihonen J., Haukka J., Taylor M., Haddad P.M., Patel M.X., Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry 2011, 168:603-609.
11. Zhu B., Ascher-Svanum H., Shi L., Faries D., Montgomery W., Marder S.R. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr. Serv. 2008, 59(3):315-317.